Dr. John Cush RheumNow
5 years 5 months ago
BC, Canada study of Lupus mortality: 6,092 SLE pts followed for 17 yrs, there were 451 deaths. Compared to population, all cause mortality was nearly 2 fold higher (HR 1.85 (1.66-2.06); excess deaths from renal (HR 3.04), INFX (2.74) & CVD (2.05) https://t.co/I0kzXNeulH https://t.co/ZVNp4Ec2gC
Dr. Jack Cush reviews and discusses more than a dozen news and journal articles from the past week on RheumNow.com.
Dr. John Cush RheumNow
5 years 5 months ago
Diary study of 79 FM, 86 RA, 33 w/ both FM/RA shows that compared to RA, pts with FM have worse daily well-being, negative affect, more isolation, inability to complete plan. FM had more perceived stigma and lower well-being. https://t.co/YZdhvYghuI
Dr. John Cush RheumNow
5 years 5 months ago
Sonelokimab is a novel trivalent nanobody aimed at IL-17A & IL-17F; tested at multiple doses vs Placebo or secukinumab in 383 plaque psoriasis pts: SON at doses 60-120 mg had efficacy similar to SEC; but SON had more Candida infx (17·4% vs 1.9% SEC) https://t.co/Nhh9UyX3i0
Literature review and metanalysis of many studies suggests that significant delay to diagnosis in axial spondyloarthritis (axSpA) exist, are longer than other rheumatic diseases and have not changed over time.
From a total of 64 studies identified the reported mean delay in diagnosing axSpA was 6.7 years (95% CI 6.2, 7.2) with high levels of heterogeneity among these studies.
A Danish cohort study examined the risk of methotrexate related liver disease risk in patients with psoriasis (PsO)and psoriatic arthritis (PsA), and found that compared to rheumatoid arthritis (RA), psoriatic patients had up to a 3 fold higher risk of liver disease.
Dr. John Cush RheumNow
5 years 5 months ago
"Dr. M McMahon distinguishes SLE presentation in different ethnicities.
-People of color have > risk for renal dz
-Black patients have higher rates of SkM and neuro dz
-Death 4X > in Asians, 6X > in Hispanics #RNL2021
"
#RNL2021 coverage from @KDAO2011
Dr. John Cush RheumNow
5 years 5 months ago
News Feature: Increased Risk of COPD in ACPA+ Pre-RA Patients
A new study shows that elevation of ACPAs before diagnosis of RA increases the risk of developing COPD and/or asthma.
https://t.co/1F8fOxpaQ0 https://t.co/GaaGcF90YD
Dr. John Cush RheumNow
5 years 5 months ago
When DOACs (Xarelto, Eliquis) used for Afib or VTE, concomitant aspirin also given (without indication) in 34%. There was no additional anti-thrombotic effect, PLUS ASA use adds 20% increased risk of non-major bleeding. Registry cohort study of 3280 pts. https://t.co/6vDw8HfDZX
Dr. John Cush RheumNow
5 years 5 months ago
2016 FDA labeling discourage quinolones (tendinopathy, interstitial nephitis) use. Since QUIN Rx have steadily dropped for UTI, sinusitis & COPD with shift to nitrofurantoin, amoxil, macrolides & tetracyclines. Still QUIN used in 15-19% of UTIs and COPD https://t.co/Yq2c8YFUog
Analysis of patients receiving anti–tumor necrosis factor α (TNFi) therapy in the British Society for Rheumatology Biologics Register (BSRBR) shows that the risk of demyelination is rare but is marginally increased by taking TNFi therapy.
Dr. John Cush RheumNow
5 years 5 months ago
Did you miss yesterday's Tuesday Night Rheumatology? Watch the replay and see how we answered questions from the webinar attendees.
https://t.co/WnnUklOmMP https://t.co/o2mRNZrUv8
Dr. John Cush RheumNow
5 years 5 months ago
News Feature: New Side Effect From mRNA COVID Vaccines?
Herpes zoster reactivation following COVID-19 vaccination in 6 patients with comorbid autoimmune/inflammatory diseases may be a new adverse event associated with the Pfizer/BioNTech mRNA vaccine.
https://t.co/GgjoIpYDkC https://t.co/sI2Fx0o05G
The lung and its pathology is uniquely tied to rheumatoid arthritis (RA) and its pathogenesis. A new study shows that elevation of anti–citrullinated protein antibodies (ACPAs) before diagnosis of RA increases the risk of developing chronic obstructive pulmonary disease (COPD) and/or asthma.
This finding is important as there are other studies showing:
